MTOR and neoplasm: Nevertheless, exploiting the predictive value of PTEN to improve patient care will rely on accurate, stringent testing for PTEN activity, and consideration of the disease subtype, the mechanism by which PTEN has been lost, the co-occurrence of other oncogenic PI3K--AKT--mTOR alterations with PTEN loss, and the extent of tumor heterogeneity is paramount.